| Gastrointestinal Involvement (Main Menu) |
|
|
| Dysmotility Syndrome in Systemic Scleroderma |
| These symptoms may occur by themselves or along with other diseases or systemic scleroderma but not in localized scleroderma, such as linear and morphea. See Types of Scleroderma. This page was written by Shelley Ensz, and has not yet been medically edited. Scleroderma (SD) affects everyone differently. Just because something is listed here does not mean that it is due to scleroderma or that an individual patient will ever experience it. See Disclaimer. |
|
|
| Dysmotility Syndrome in Scleroderma |
| Dysmotility syndrome refers to muscles in the gastrointestinal tract not working properly. This can include the throat (esophagus), stomach, and bowels. When the stomach is affected, it is often called gastroparesis. When it affects the bowels, it may be called intestinal pseudo-obstruction. ISN. (Also see: Esophagus, Gastroparesis, and Bowel Involvement) |
| Dysmotility syndrome is a vague, descriptive term used to describe diseases of the muscles of the gastrointestinal tract (esophagus, stomach, small and large intestines) in which the muscles do not work normally (hence the term dysmotility). Other terms that are sometimes used for dysmotility problems are gstroparesis when the stomach is involved, and chronic intestinal pseudo-obstruction when the intestines and stomach are involved. MedicineNet. |
| What are Dysmotilities? Symptoms, diagnosis, treatments, and support. Gastroparesis and Dysmotilities Association. |
| Esophageal dysmotility in scleroderma: A prospective study of 183 cases. Esophageal motor disorders are frequently seen in scleroderma, especially in cases with clinical symptoms, but are not associated with a specific form of the disease. Lahcene M. (PubMed) Gastroenterol Clin Biol. 2009 Jun-Jul;33(6-7):466-9. |
| Motility Disorders. Achalasia is a neurogenic esophageal motility disorder characterized by impaired esophageal peristalsis, a lack of lower esophageal sphincter relaxation during swallowing, and an elevation of lower esophageal sphincter resting pressure. Symptomatic diffuse esophageal spasm is part of a spectrum of motility disorders characterized variously by nonpropulsive contractions, hyperdynamic contractions, or elevated lower esophageal sphincter pressure. Merck Manuals. |
| Symptoms of Dysmotility |
| Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma. In scleroderma patients dyspepsia (mainly gastric fullness), restricted distension of the gastric antrum and diffuse gastrointestinal dysmotility are frequent features. These defects are independent from the occurrence of autonomic neuropathy. Di Ciaula A. (PubMed) BMC Gastroenterol. 2008 Feb 27;8:7. |
| Diagnosis of Dysmotility |
| Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract (GIT) dysmotility. The findings indicated that anti-M3R antibody very frequently appears in patients with SSc, which is accompanied by severe GIT involvement, suggesting that M3R-mediated enteric cholinergic neurotransmission may provide a pathogenic mechanism for GIT dysmotility in SSc. Kawaguchi Y, (PubMed) Ann Rheum Dis. 2009 May;68(5):710-4. |
| A new method for evaluation of intestinal muscle contraction properties: studies in normal subjects and in patients with systemic sclerosis. Systemic sclerosis patients had increased stiffness and impaired muscle dynamics of the duodenum. Decreased muscle function and increased wall stiffness may explain the GI symptoms reported in this patient group. PubMed. Neurogastroenterol Motil. 2007 Jan;19(1):11-9. (Also see: Bowel Dysfunction) |
| Treatment and Management of Dysmotility |
| Transcutaneous Electrical Nerve Stimulation (TENS) Improves Upper GI Symptoms and Balances the Sympathovagal Activity in Scleroderma Patients. TENS at GI acupoints offers a potential option in the treatment of upper GI symptoms, but further study is necessary. PubMed. Dig Dis Sci. 2007 Mar 20. |
| Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis. Lifestyle and medical therapy approaches are preferred as they often improve and/or ameliorate symptoms. Surgery is only recommended with serious, rare complications. Alternative therapies such as acupuncture-based therapies are well tolerated, with clinical improvement and may be of potential therapeutic benefit for systemic sclerosis gastrointestinal dysmotility. PubMed. Aliment Pharmacol Ther. 2006 Mar 15;23(6):691-712. |
| Domperidone Warning |
| FDA Alert: Detention without Physical Examination of Domperidone, brands names Motilium, Euciton, Cilroton, Praxis, Seronex, Emiken. Domperidone is not approved for any use in the U.S. There have been several published reports and case studies of cardiac arrhythmias, cardiac arrest and sudden death in patients receiving an intravenous form of domperidone. U.S. Food and Drug Administration (FDA). 2004. |
| Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders. Several cases of QT prolongation and ventricular tachyarrhythmia have been reported with domperidone, a gastrokinetic and antiemetic agent available worldwide but still under investigation in the United States. American Heart Association. Circulation 2000:102:1883. |
| Correlation of Dysmotility with other Complications |
| Thyroid-intestinal motility interactions summary. Thyroid diseases may be related to gastrointestinal motility symptoms. Such symptoms can vary in degree and, sometimes, are the only clue of a thyroid disease or, at least, the first. PubMed. Minerva Gastroenterol Dietol. 2004 Dec;50(4):305-15. (Also see: Thyroid Disease) |
| Dysmotility Patient and Caregiver Stories |
| Amanda: Diffuse Scleroderma Systemic Sclerosis I am thirty-nine years old and was diagnosed with diffuse scleroderma systemic sclerosis in August 2007... |
| Research on Dysmotility |
| Human enteric neuropathies: morphology and molecular pathology. The aim of this study is to review current understanding of the molecular and morphological pathology of the enteric neuropathies affecting motor function of the human gastrointestinal tract. PubMed. Neurogastroenterol Motil. 2004 Oct;16(5):515-31. (Also see: Causes of Scleroderma: Molecular Defect) |
